NOVORAPID CHU FLEXPEN

Novorapid Chu Flexpen Adverse Events Reported to the FDA Over Time

How are Novorapid Chu Flexpen adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Novorapid Chu Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Novorapid Chu Flexpen is flagged as the suspect drug causing the adverse event.

Most Common Novorapid Chu Flexpen Adverse Events Reported to the FDA

What are the most common Novorapid Chu Flexpen adverse events reported to the FDA?

Hypoglycaemia	114 (9.91%)
Anti-insulin Antibody Positive	79 (6.87%)
Diabetes Mellitus Inadequate Contro...	49 (4.26%)
Suicide Attempt	42 (3.65%)
Hyperglycaemia	41 (3.57%)
Intentional Overdose	40 (3.48%)
Blood Glucose Fluctuation	36 (3.13%)
Blood Glucose Increased	36 (3.13%)
Hypoglycaemic Coma	29 (2.52%)
Anti-insulin Antibody	26 (2.26%)
Anti-insulin Antibody Increased	26 (2.26%)
	Show More
Hepatic Function Abnormal	26 (2.26%)
Hypoglycaemic Encephalopathy	17 (1.48%)
Hypoglycaemic Unconsciousness	16 (1.39%)
Drug Hypersensitivity	15 (1.3%)
Diabetic Ketoacidosis	14 (1.22%)
Glycosylated Haemoglobin Increased	13 (1.13%)
Alanine Aminotransferase Increased	11 (.96%)
Aspartate Aminotransferase Increase...	11 (.96%)
Erythema Multiforme	11 (.96%)
Injection Site Erythema	11 (.96%)
Liver Disorder	11 (.96%)
Rash	11 (.96%)
Blood Glucose Decreased	9 (.78%)
Loss Of Consciousness	8 (.7%)
Oedema Peripheral	8 (.7%)
Weight Increased	8 (.7%)
Autoantibody Positive	7 (.61%)
Blood Insulin Increased	7 (.61%)
Fracture	7 (.61%)
Injection Site Induration	7 (.61%)
Interstitial Lung Disease	7 (.61%)
Erythema	6 (.52%)
Vomiting	6 (.52%)
Abdominal Pain	5 (.43%)
Anti-gad Antibody Positive	5 (.43%)
Ascites	5 (.43%)
Cardio-respiratory Arrest	5 (.43%)
Device Failure	5 (.43%)
Diabetic Neuropathy	5 (.43%)
Face Oedema	5 (.43%)
Hepatitis	5 (.43%)
Injection Site Pain	5 (.43%)
Nasopharyngitis	5 (.43%)
Neuralgia	5 (.43%)
Oedema	5 (.43%)
Pericardial Effusion	5 (.43%)
Pleural Effusion	5 (.43%)
Allodynia	4 (.35%)
Cerebral Infarction	4 (.35%)
Disseminated Intravascular Coagulat...	4 (.35%)
Drug Eruption	4 (.35%)
Dysphonia	4 (.35%)
Dyspnoea	4 (.35%)
Hepatitis Acute	4 (.35%)
Hyperinsulinaemia	4 (.35%)
Injection Site Swelling	4 (.35%)
Insomnia	4 (.35%)
Insulin Autoimmune Syndrome	4 (.35%)
Nausea	4 (.35%)
Premature Rupture Of Membranes	4 (.35%)
Pyrexia	4 (.35%)
Threatened Labour	4 (.35%)
Wrong Drug Administered	4 (.35%)
Burning Sensation	3 (.26%)
Cardiac Arrest	3 (.26%)
Cerebral Haemorrhage	3 (.26%)
Death	3 (.26%)
Decreased Appetite	3 (.26%)
Dehydration	3 (.26%)
Diplopia	3 (.26%)
Eczema	3 (.26%)
Feeling Abnormal	3 (.26%)
Gamma-glutamyltransferase Increased	3 (.26%)
Gastroenteritis	3 (.26%)
Generalised Oedema	3 (.26%)
Hepatic Enzyme Increased	3 (.26%)
Hepatitis Fulminant	3 (.26%)
Hypoglycaemia Unawareness	3 (.26%)
Hypothermia	3 (.26%)
Ill-defined Disorder	3 (.26%)
Injection Site Pruritus	3 (.26%)
Injection Site Reaction	3 (.26%)
Liver Function Test Abnormal	3 (.26%)
Localised Oedema	3 (.26%)
Malaise	3 (.26%)
Maternal Condition Affecting Foetus	3 (.26%)
Osteomyelitis	3 (.26%)
Pemphigoid	3 (.26%)
Pregnancy	3 (.26%)
Pruritus Generalised	3 (.26%)
Retinal Haemorrhage	3 (.26%)
Sepsis	3 (.26%)
Toxic Skin Eruption	3 (.26%)
Weight Decreased	3 (.26%)
Abdominal Pain Upper	2 (.17%)
Abortion	2 (.17%)
Anti-insulin Receptor Antibody Posi...	2 (.17%)
Back Pain	2 (.17%)
Body Temperature Decreased	2 (.17%)
Brain Oedema	2 (.17%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Novorapid Chu Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Novorapid Chu Flexpen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Novorapid Chu Flexpen

What are the most common Novorapid Chu Flexpen adverse events reported to the FDA?

Glucose Metabolism Disorders	236 (20.52%)
Immunology And Allergy	147 (12.78%)
Metabolic, Nutritional And Blood Ga...	97 (8.43%)
Neurological	59 (5.13%)
Hepatic And Hepatobiliary	56 (4.87%)
Epidermal And Dermal Conditions	47 (4.09%)
Medication Errors	47 (4.09%)
Suicidal And Self-injurious Behavio...	43 (3.74%)
Administration Site Reactions	36 (3.13%)
Hepatobiliary	31 (2.7%)
Gastrointestinal Signs	18 (1.57%)
	Show More
Infections - Pathogen Unspecified	18 (1.57%)
Encephalopathies	17 (1.48%)
Allergic Conditions	16 (1.39%)
Diabetic Complications	14 (1.22%)
Physical Examination Topics	13 (1.13%)
Hematology Investigations	10 (.87%)
Endocrine Investigations	9 (.78%)
Respiratory	9 (.78%)
Bone And Joint Injuries	8 (.7%)
Cardiac Arrhythmias	8 (.7%)
Central Nervous System Vascular	8 (.7%)
Maternal Complications Of Labour An...	8 (.7%)
Body Temperature Conditions	7 (.61%)
Lower Respiratory Tract Disorders	7 (.61%)
Injuries	6 (.52%)
Peripheral Neuropathies	6 (.52%)
Pericardial	5 (.43%)
Peritoneal And Retroperitoneal Cond...	5 (.43%)
Pleural	5 (.43%)
Procedural And Device Related Injur...	5 (.43%)
Psychiatric	5 (.43%)
Vision	5 (.43%)
Autoimmune	4 (.35%)
Coagulopathies And Bleeding Diathes...	4 (.35%)
Electrolyte And Fluid Balance Condi...	4 (.35%)
Fatal Outcomes	4 (.35%)
Fetal Complications	4 (.35%)
Sleep Disorders	4 (.35%)
Abortions And Stillbirth	3 (.26%)
Appetite And General Nutritional	3 (.26%)
Chemical Injury And Poisoning	3 (.26%)
Mental Impairment	3 (.26%)
Musculoskeletal And Connective Tiss...	3 (.26%)
Pregnancy, Labour, Delivery And Pos...	3 (.26%)
Retina, Choroid And Vitreous Hemorr...	3 (.26%)
Therapeutic And Nontherapeutic Effe...	3 (.26%)
Angiedema And Urticaria	2 (.17%)
Anxiety Disorders	2 (.17%)
Bone, Calcium, Magnesium And Phosph...	2 (.17%)
Coronary Artery	2 (.17%)
Fungal Infectious	2 (.17%)
Gallbladder	2 (.17%)
Gastrointestinal Neoplasms Malignan...	2 (.17%)
Gastrointestinal Ulceration And Per...	2 (.17%)
Increased Intracranial Pressure And...	2 (.17%)
Injuries By Physical Agents	2 (.17%)
Leukemias	2 (.17%)
Lifestyle Issues	2 (.17%)
Movement Disorders	2 (.17%)
Muscle	2 (.17%)
Neurological Disorders Of The Eye	2 (.17%)
Renal And Urinary Tract Disorders C...	2 (.17%)
Seizures	2 (.17%)
Skin And Subcutaneous Tissue	2 (.17%)
Skin Appendage Conditions	2 (.17%)
Viral Infectious	2 (.17%)
Cardiac And Vascular Disorders Cong...	1 (.09%)
Cardiac And Vascular Investigations	1 (.09%)
Cranial Nerve Disorders	1 (.09%)
Eye	1 (.09%)
Gastrointestinal Motility And Defec...	1 (.09%)
Hematological And Lymphoid Tissue T...	1 (.09%)
Hemolyses And Related Conditions	1 (.09%)
Metabolic And Nutritional Disorders...	1 (.09%)
Neonatal And Perinatal Conditions	1 (.09%)
Nephropathies	1 (.09%)
Ocular Neuromuscular	1 (.09%)
Ocular Sensory Symptoms	1 (.09%)
Protein And Chemistry Analyses	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Novorapid Chu Flexpen, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Novorapid Chu Flexpen is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.